Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 40.5% in February

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 92,200 shares, a decline of 40.5% from the January 31st total of 154,900 shares. Approximately 5.3% of the company’s shares are sold short. Based on an average daily volume of 370,300 shares, the short-interest ratio is presently 0.2 days.

Avenue Therapeutics Stock Down 12.0 %

Shares of NASDAQ:ATXI opened at $1.10 on Friday. Avenue Therapeutics has a 12-month low of $1.05 and a 12-month high of $15.00. The company’s fifty day moving average is $1.60 and its two-hundred day moving average is $2.04. The company has a market cap of $2.26 million, a P/E ratio of 0.06 and a beta of -0.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Boothbay Fund Management LLC purchased a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned approximately 2.00% of Avenue Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.34% of the company’s stock.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.